Indaptus Therapeutics, Inc. (INDP)

NASDAQ: INDP · USD

$3.30

-0.00 (-0.1%)· Recorded snapshot

Market cap	506.8M
Net income (ttm)	-15.4M
EPS (ttm)	-$0.47
Shares out	153.6M
Volume	206,612
Beta	0.97

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -15.4M
EPS (ttm): -$0.47
Market cap: 506.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ถือ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-318

P25 n/aP50 n/aP75 n/a

ROIC-113.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All INDP indicators

Market & fundamental data

Available fields

172

Groups with data

Currency

USD

Showing 172 of 172 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001857044
Company name	Indaptus Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	45339J204
Earnings date	2026-11-11
Earnings time	bmo
Employees	5
Employees change	-2
Employees growth	-28.57%
Enterprise value	$495.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US45339J2042
Last 10-K release date	2026-03-17
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split date	2025-06-27
Last stock split type	Reverse
Market cap	$506.8M
Market cap category	Small-Cap
Next earnings date	2026-11-11
Options	No
Price	$3.30
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	INDP
U.S. state	New York
Website	https://indaptusrx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-14.27%
FCF / EV yield	-2.85%
FCF yield	-2.79%
P/B ratio	38.72x
Price / tangible book value	46.32x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-3.1M
ROA	-98.08%
ROA (5Y)	-66.56%
ROCE	-129.9%
ROE	-318.04%
ROE (5Y)	-189.94%
ROIC	-113.73%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	8
EPS growth years	2
Net income growth quarters	2
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-14.8M
EPS	$-0.47
FCF per share	$-0.10
Financing cash flow	$20.1M
Free cash flow	$-14.7M
Free cash flow minus SBC	$-15.8M
Investing cash flow	$-4M
Net cash flow	$1.4M
Net income	$-15.4M
Operating cash flow minus SBC	$-15.8M
Operating income	$-14.8M
Stock-based compensation	$1.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$0.09
Debt / equity	0
Long-term assets	$0
Long-term liabilities	$0
Net cash (debt)	$11.6M
Net cash / market cap	2.19%
Net debt / equity	-1.02
Piotroski F-Score	2
Shareholders' equity	$11.4M
Tangible book value	$11.4M
Tangible book value per share	$0.09
Total assets	$12M
Total cash	$11.6M
Total debt	$0
Total liabilities	$615,426
WACC	9.6%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$12M
Current liabilities	$615,426
Current ratio	19.48
Net working capital	$-181,290
Quick ratio	18.77
Working capital	$11.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-7,142.37%
Dividend yield	0%
Shareholder yield	-7,142.37%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$2.36
1D price change	-0.15%
1M price change	-10.91%
1M total return	-10.91%
1W price change	15.88%
1W total return	15.88%
1Y price change	-3.38%
1Y return CAGR	-3.38%
1Y total return	-3.38%
20-day SMA	$2.72
200-day SMA	$2.29
3M price change	68.14%
3M total return	68.14%
3Y price change	-94.11%
3Y return CAGR	-61.08%
3Y total return	-94.11%
50-day SMA	$2.47
50-day SMA vs 200-day SMA	50over200
52-week high	$5.96
52-week high date	2026-06-04
52-week low	$0.92
52-week low date	2026-08-18
5Y price change	-98.35%
5Y return CAGR	-56.01%
5Y total return	-98.35%
All-time high	$807.24
All-time high date	2021-09-15
All-time low	$0.92
All-time low date	2026-05-22
Average true range (ATR)	$0.36
Average volume	413.8K
Beta (1Y)	0.44
Beta (2Y)	1.29
Beta (5Y)	0.97
Change from 52-week high	-44.63%
Change from 52-week low	258.7%
Change from all-time high	-99.58%
Change from all-time low	272.83%
Change from open	-3.79%
Day's gap	3.78%
Dollar volume	$681,820
High price	$3.43
Low price	$3.25
Monthly RSI	27.7
Open price	$3.43
Position in 52-week range	27.78%
Premarket change	-0.15%
Premarket close	$3.31
Premarket price	$3.30
Premarket volume	543
Previous close	$3.31
Price vs 150-day SMA	45.34%
Price vs 20-day SMA	26.24%
Price vs 200-day SMA	49.85%
Price vs 50-day SMA	39.04%
Relative volume	0.5
RSI	60.89
Sharpe ratio	0.82
Sharpe ratio (3Y)	-0.04
Sharpe ratio (5Y)	-0.12
Sortino ratio	1.68
Sortino ratio (3Y)	-0.03
Sortino ratio (5Y)	-0.15
Volume	206.6K
Weekly RSI	56.28
YTD price change	17.87%
YTD total return	17.87%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	45.3M
Float percentage	29.52%
Shares change (QoQ)	959.92%
Shares change (YoY)	7,142.37%
Shares held by insiders	70.48%
Shares held by institutions	0.3%
Shares outstanding	153.6M
Short % of float	1.89%
Short % of shares	0.56%
Short ratio	1.2 days

Deeper analysis on INDP

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this INDP report

Is a complete INDP research report available?

No complete published report is available for Indaptus Therapeutics, Inc. (INDP) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Indaptus Therapeutics, Inc. (INDP)

Price

Financial snapshot

Fair-value bridge

Latest news · INDP

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All INDP indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on INDP

Frequently asked questions